Previous 10 | Next 10 |
Mid-Con Energy Partners (NASDAQ: MCEP ) +154% on Q1 results . More news on: Mid-Con Energy Partners, LP, IDEAYA Biosciences, Inc., iQIYI, Inc., Stocks on the move, , Read more ...
Goal of XCART collaboration to optimize XCART process, develop manufacturing processes and to ultimately dose non-Hodgkin lymphoma (NHL) patients Pharmsynthez to act as primary contract research organization coordinating activities throughout collaboration Academic Institutions i...
Edesa Biotech (NASDAQ: EDSA ) +218% on launch of COVID-19 study in Canada. More news on: Edesa Biotech, Inc., Brickell Biotech, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...
Live video moderated discussion with CEO, Jeffrey Eisenberg, on Tuesday, June 16 th at 12:00 PM ET, immediately followed by an interactive Q&A session FRAMINGHAM, MA / ACCESSWIRE / June 8, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmac...
Pyxus International (NYSE: PYX ) -26% . More news on: Pyxus International, Inc., Nano Dimension Ltd., Medigus Ltd., Stocks on the move, , Read more ...
Xenetic Biosciences (NASDAQ: XBIO ) is up 29% premarket in reaction to its announcement that it has entered into a research funding and option agreement with Scripps Research to advance the development of the XCART technology for B cell malignancies. More news on: Xeneti...
- Represents significant milestone in strategic development plan to advance XCART through academic collaborations - - Provides access to leading research institution with world renowned immunology expertise - - Company engaged in ongoing discussions to potentially add additional ac...
- Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its XCART™ CAR T therapy platform - - Continuing to progress discussions to secure academic collaborations to advance the XCART platform - - Cash on hand expecte...
Presentation with live audio webcast on Wednesday, April 22 at 11:30 AM ET, immediately followed by an interactive Q&A session FRAMINGHAM, MA / ACCESSWIRE / April 15, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused...
Xenetic Biosciences (NASDAQ: XBIO ): FY GAAP EPS of -$6.33 misses by $0.77 . More news on: Xenetic Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...